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withdrawal of therapy in mild persistent asthmatics, asymptomatic on low-dose
inhaled corticosteroids (ICS), we studied 87 asthmatic patients regularly treated
with ICS for at least 6 months. At the enrollment visit (T1), 71 on ICS were
asymptomatic over the past 3 months and discontinued asthma treatment.
Symptoms and PEF were then monitored for up to 3 months or until symptoms
recurred (T2). At T1 and T2, all subjects underwent methacholine challenge and
sputum induction.
Thirtynine out of 71 patients experienced symptom recurrence. At T1, clinical
and functional data and sputum eosinophilia between patients with or without
recurrence of symptoms were similar. Age 440 yr, and disease duration 45 yr were
significantly associated with recurrence of asthma symptoms, while the presence of
allergic rhinitis, low baseline FEV1 and untreated time span 460 months showed a
trend to be associated with symptoms recurrence. At T2, symptoms, pulmonary
function, bronchial hyperresponsiveness and sputum eosinophilia deteriorated in
patients with symptom recurrence but not in patients without symptom recur-
rence.
In conclusion, age and asthma duration were the best predictors of symptom
recurrence in mild persistent asthmatics who withdrew pharmacological therapy, as
recommended in the step-down of international guidelines.
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Predictors of asthma recurrence 623Introduction
Asthma is a chronic inflammatory disease of the
airways which usually requires, in patients with
persistent symptoms, regular treatment with
inhaled corticosteroids (ICS) and frequently with
long-acting bronchodilators too. When asthma is
under control for a long period, a stepwise
reduction of maintenance therapy should be
attempted in order to reach the minimum therapy
required to maintain control.1 Eventually, when
asthma has been under control for at least 3 months
on the lowest level of antiinflammatory therapy
(low dose ICS monotherapy, as in mild persistent
asthma), regular treatment may be withdrawn;
however, international asthma guidelines recom-
mend close monitoring of these asthmatic subjects,
because asthma symptoms can frequently recur.1
Some papers have demonstrated the recurrence
of asthma symptoms after 1–12 month cessation of
ICS in about 50% of regularly treated patients.2–6
The recurrence of asthma symptoms can also be
observed during a rapid progressive reduction of
the dose of ICS treatment.5,7–10 However, in these
studies patients were treated with moderate to
high doses of ICSs, and the reduction until cessation
of regular treatment was done in a short period of
time. On the contrary, no study has evaluated the
rate of asthma recurrence in mild persistent
asthmatics, well controlled on monotherapy with
low dose ICS, after cessation of treatment as
recommended by the step-down procedure of the
international guidelines.
Few clinical and functional findings have been
shown able to predict asthma recurrence after
cessation of regular ICS treatment. Persistence of
bronchial hyperresponsiveness did not predict early
recurrence of asthma symptoms after cessation of
ICS therapy,5 but the degree of bronchial hyperre-
sponsiveness and sputum eosinophil counts pre-
dicted asthma exacerbation during stepwise dose
reduction of ICS.7 Jatakanon et al.8 and Giannini
et al.6 demonstrated that the recurrence of asthma
symptoms after reduction or withdrawal of treat-
ment was associated with high sputum eosinophil
percentages observed when subjects were still
being treated and were asymptomatic. However,
in all these studies a small selected number of
subjects was evaluated.
The aim of the present study was to identify
possible predictors of asthma exacerbation after
withdrawal of therapy in a large number of mild
persistent stable asthmatics on low-dose ICS. Our
study also had the purpose to verify the rate of
asthma recurrence when the lower level of regular
anti-asthma treatment was withdrawn, as recom-mended in the step-down by international asthma
guidelines.Subjects and methods
Subjects
Eighty-seven asthmatic patients regularly treated
with ICS for at least 6 months were selected for
study from our outpatient clinic. At the time of
diagnosis (at least 6 months before), asthma
severity had been rated as being mild-to-moderate,
according to international guidelines.1 After diag-
nosis, the patients had then been regularly treated
with ICSs for at least 6 months, with or without
regular long-acting bronchodilators, and had per-
formed serial clinical and functional evaluations in
our asthma clinic. To be included in the present
study, they had been asymptomatic and stable on
low-dose ICS (beclomethasone dipropionate, BDP,
250 mg b.i.d. or equivalent) over the past 3 months;
the stability of asthma should be confirmed by
monitoring symptom score and PEF variability in
the last 2 weeks, as reported in the study protocol.
Therefore, only 71 adult patients (30 male, 41
female, mean age 35.8714.8 yr, range: 17–72)
entered the study. Forty-four subjects were atopic,
as shown by positive skin prick tests to common
inhalant allergens; 52 patients were nonsmokers,
and 11 were ex-smokers. All patients had perennial
asthma, with no relationship with pollen season.
Study protocol
This was an observational study. At the beginning of
the study (T1), while still taking BDP 250 mg b.i.d.,
all subjects recorded symptom score and peak
expiratory flow rate (PEF) twice daily on a diary
card over a 2-week run-in period. At the end of run-
in period, on two different days, all subjects
underwent baseline spirometry, methacholine chal-
lenge test and sputum induction to evaluate
inflammatory cell percentages.
Inclusion criteria were: diurnal and nocturnal
symptoms score ¼ 0, low PEF variability (Amplitu-
de%mean o10%), and no use of rescue b2-agonists,
throughout of the 2-week run-in period. Seven-
tyone subjects fulfilled inclusion criteria and
stopped ICS treatment. All 71 subjects continued
to monitor PEF twice daily and symptom score for 3
months or until asthma symptoms recurred. Diurnal
and/or nocturnal symptom score X2, and/or a
daily Amplitude%mean420% on 2 consecutive days
was considered as asthma recurrence. All subjects
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asthma symptoms recurred. At the end of the study
(T2), i.e. either within 5 days from the beginning of
asthma symptoms or 3 months after treatment
cessation in stable subjects, all subjects repeated
methacholine challenge test and sputum induction.
The protocol was approved by the local Ethical
Committee. Informed written consent was given by
all patients.
Methacholine challenge test
Methacholine (Sigma, St. Louis, MO, USA) was
delivered by a Devilbiss 646 jet nebulizer using
the procedure described elsewhere.11 Briefly,
phosphate buffered saline was inhaled first, fol-
lowed every two minutes by methacholine inhala-
tion from 0.04 to 3.2mg of cumulative doses of
methacholine in different steps. FEV1 was mea-
sured 2min after each step. The test was stopped
when FEV1 fell by 20% or more below the
postdiluent value, and PD20FEV1 (the cumulative
dose producing 20% fall in FEV1) was computed.
Symptom score and peak expiratory (PEF)
flow monitoring
All subjects monitored PEF by means of a mini-
Wright Peak Flow Meter (PFM) two times daily
(early in the morning and at bedtime before drug
inhalation) for 14 consecutive days at the beginning
of the study (run-in period) and then up to 3 months
(T2). Subjects were carefully instructed with the
use of PFM. They were required to perform three
blows in the PFM and record the highest value on a
diary card. Subjects were also instructed to
measure PEF each time they had dyspnoea or
wheeze, and to repeat measurements 10min after
b2-agonist inhalation. PEF variability was assessed
as daily Maximal Amplitude (MA: (highest-lowest
value) /mean daily value  100). Patients also
recorded daily asthma symptoms (cough, wheeze
and/or dyspnoea) on a diary card according to score
ranging from 0 to 5 for diurnal symptoms (0 ¼ no
symptoms during the day; 1 ¼ symptoms for one
short time period during the day; 2 ¼ symptoms for
two or more short time periods during the day;
3 ¼ symptoms for most of the day which did not
affect normal daily activities; 4 ¼ symptoms for
most of the day which affect normal daily activ-
ities; 5 ¼ symptoms so severe that the patient
could not to go to work or attend to normal daily
activities), and from 0 to 4 for nocturnal symptoms
(0 ¼ no symptoms during the night; 1 ¼ symptoms
causing the patient to wake up once or earlier thanusual; 2 ¼ symptoms causing the patient to wake
up twice or more, including waking up earlier than
usual; 3 ¼ symptoms causing the patient to stay
awake for most of the night; 4 ¼ symptoms so
severe that the patient did not sleep at all).6
Mean symptom score at T2 was computed
considering the last 7 days of monitoring. We
compared the weekly mean of symptom score, PEF
and PEF maximal amplitude of the run-in period
with the same values obtained during the last week
of the study protocol, either during symptom
recurrence or 3 months after treatment cessation.
Sputum induction
Sputum was induced according to the method
previously described.12 Hypertonic saline was neb-
ulized with an ultrasonic nebulizer (Sirius, Tech-
nomed, Firenze, Italy) with a 2.8ml/min output,
and was inhaled for 5min periods for up to 30min.
NaCl solution was increased at intervals of 10min
from 3% to 4% to 5%. FEV1 was measured before and
every 5min during hypertonic saline inhalation.
Every 5min after the start of nebulization, subjects
were asked to rinse their mouth, to discard saliva
and then to cough sputum into a clean container.
The nebulization was stopped after 30min or when
FEV1 fell by 20% or more from baseline. Anytime
during the induction, the inhalation was stopped in
the subjects who experienced symptoms of bronch-
oconstriction, and FEV1 was then measured.
Sputum processing
The whole sputum sample was diluted with an
equal volume of 0.1% dithiotreithol (Sputasol;
Unipath Ltd, Basingstoke, UK). Samples were
treated as previously reported.12 Macrophage,
lymphocyte, neutrophil, eosinophil percentages
were expressed as percent of total inflammatory
cells, excluding squamous cells.
The upper limit of normal range for sputum
eosinophils was set at 2% derived from a group of
normal subjects.13
Statistical analysis
FEV1, PEF, indices of PEF variability and all clinical
findings are expressed as mean (standard deviation,
SD). PD20FEV1 methacholine is expressed as geo-
metric mean and was log transformed for statistical
analysis. Sputum eosinophil percentages are ex-
pressed as median [range].
Analysis of variance (ANOVA) was used to




























Figure 1 Kaplan Meier curve of the time to the
recurrence of asthma symptoms after cessation of
treatment in 71 examined subjects.
Predictors of asthma recurrence 625data (clinical findings, FEV1, logPD20FEV1 Metha-
choline and Mean PEF), and Kruskal–Wallis or
Wilcoxon tests were used for non-normally distrib-
uted data (PEF maximal Amplitude, Sputum Eosi-
nophil percentages). Predictors for asthma
recurrence were evaluated by contingency tables,
and related predictive values were also evaluated.
Cut-off values for numerical predictors were: 40 yr
for age, 5 yr for disease duration and untreated
time span, 80% for FEV1, 0.4mg for PD20FEV1
methacholine, 2% for sputum eosinophilia and 50%
for sputum neutrophilia. Logistic regression analy-
sis was performed, considering as dependent
variable the outcome of asthma after cessation of
treatment (recurrence vs. non-recurrence of asth-
ma symptoms) and as independent variables all
baseline variables which had demonstrated a
significant correlation or a trend with the outcome
of asthma in the univariate analysis. A level of
probability lower than 5% was considered as
significant.Results
Out of 87 screened subjects, 71 fulfilled the
inclusion criteria, when examined after 3 months
at least of regular treatment with low dose ICS.
They were asymptomatic, with no use of rescue
medication and stable PEF in the last 2 weeks
before randomization. Mean FEV1 (in percent of
predicted value) was greater than 80% in 61 out of
71 patients; in the remaining 10 patients, FEV1 was
however at the best value (+5%) observed during
the previous period (at least 6 months) of observa-
tion in our asthma clinic. Despite clinical and
functional stability, 60 out of 71 patients (86%)
were still hyperreactive to methacholine (PD20FE-
V1o1mg) and 30 had increased percentages of
eosinophils in the induced sputum (X2%).
Within 3 months after treatment cessation, 39
patients had a recurrence of asthma symptoms
(diurnal or nocturnal symptom X2 on two con-
secutive days) and/or increased PEF variability,
whereas 32 remained asymptomatic and stable.
The mean time to the recurrence of asthma
symptoms was 37729 days from cessation of
treatment, with 56% of patients experiencing
asthma recurrence in the first month (Fig. 1). At
the time of enrollment, there was no difference in
atopy and rhinitis prevalence, FEV1% of predicted,
PD20FEV1 methacholine, eosinophil or other in-
flammatory cell percentages in sputum, and clinical
data obtained by diary card during the run-in,
between patients with or without symptom recur-
rence (Tables 1 and 2). Age, disease duration (timefrom the beginning of symptoms) and untreated
time span tended to be greater in patients who
subsequently exacerbated, although the difference
was not statistically significant.
Clinical and functional findings that might be
associated with the recurrence of asthma are
reported in Table 3, as well as their positive and
negative predictive values. Age440 yr, and disease
duration 45 yr were significantly associated with
recurrence of asthma symptoms, while the pre-
sence of allergic rhinitis, low baseline FEV1,
previous or current smoking habit and untreated
time span460 months tended to be associated with
recurrence of asthma symptoms, without reaching
statistical significance. Combining age440 yr and
disease duration45 yr yielded a positive predictive
value of 94.1%. Baseline methacholine responsive-
ness and sputum inflammatory cell counts showed
no predicting value for asthma symptom recur-
rence.
Logistic regression analysis showed than both age
and disease duration were independent predictors
of asthma recurrence (Table 4), while current or
previous smoking history was a negative predictor
of asthma exacerbations after cessation of regular
treatment.
Functional findings and sputum analysis were
available at T2 in 51 out of 71 patients. At T2,
symptoms, pulmonary function, bronchial hyperre-
sponsiveness and PEF variability deteriorated in
patients with symptom recurrence, but not in
stable patients (Table 5). Patients with symptom
recurrence had a higher percentage of sputum
eosinophils at T2 than at baseline (Po0:01), while
this increase was not observed in stable patients
(Fig. 2). The presence of viral respiratory infection
(acute rhinitis, throat pain, cough and/or fever) in
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Age, yr 32.4712.5 38.5715.9 0.07
Sex, m/f 16/16 14/25 ns
Smoke, no/yes/ex 20/3/9 32/5/2 ns
Atopy, yes/no 22/10 23/16 ns
BMI 23.373.7 23.373.6 ns
Baseline FEV1, L 3.470.9 3.170.9 ns
Baseline FEV1, % pred 94.0715.0 98.0714.4 ns
PD20 FEV1 methacholine, (mg, GM) 0.256 0.250 ns
Disease duration, yr 8.876.7 11.577.7 ns
Treatment duration, months 40.6745.0 33.373.0 ns
Untreated time span, months 66.0777.5 83.4768.9 ns
Allergic rhinitis, yes/no 14/18 12/28 ns
Symptom score, during run-in 0 0 ns
MA%mean, during run-in 3.772.4 4.673.9 ns
Mean7SD.






Baseline M%, median[range] 47.9[5.8–90.1] 47.8[9.3–86.8] ns
Baseline L%, median[range] 0.3[0–5] 0[0–2.2] ns
Baseline N%, median[range] 47.8[9.1–88.4] 49.5[7.4–88.8] ns
Baseline E%, median[range] 1.3[0–12.8] 1.8[0–56.5] ns
Table 3 Baseline predictors of recurrence of asthma symptoms.
w2 P PPV, % NPV, % Sensitivity, % Specificity, %
Age4 40 yr 10.5 0.001 82.6 58.3 48.7 87.5
Atopy 0.72 0.39 51.0 38.0 59.0 31.0
Rhinitis 3.47 0.06 33.3 39.0 24.4 62.5
Smoke (yes-ex) 3.42 0.06 37.8 38.5 21.8 62.5
Disease duration 45 yr 5.61 0.01 64 66.7 82.0 63.3
Untreated time span 460 months 2.75 0.09 63.3 57.6 57.6 22.6
Age4 40 yr and disease duration 45 yr 13.86 0.0002 94.1 57.1 41.0 96.9
Sputum eosinophils42% 0.023 0.87 54.0 44.0 36.0 62.0
Sputum neutrophils o50% 0.56 0.4 60.0 49.0 47.0 62.0
PD20Meth o0.40mg 0.08 0.77 52.0 44.0 34.0 62.0
FEV1o 80% 3.12 0.07 60.0 70.0 92.3 53.3
PPV: positive predictive value; NPV: negative predictive value.
Table 4 Logistic regression analysis of asthma
symptom recurrence.
Independent variables OR CI P
Age 8.847 2.29–34.14 0.002
Disease duration 6.142 1.59–23.68 0.008
Smoking status 0.188 0.047–0.754 0.018
M. Tonelli et al.626the few days preceding the recurrence of asthma
symptoms was reported by 14 out of 39 subjects.Discussion
This study shows that the cessation of low-dose
inhaled corticosteroid therapy, as recommended by
ARTICLE IN PRESS
Table 5 Clinical and functional findings and sputum eosinophilia at baseline (T1) and at the end of the study
(T2) in patients with or without symptom recurrence.
T1 T2 P
Without symptom recurrence n ¼ 27 FEV1% pred 95.8713.4 95.2711.8 ns
PD20 methacholine, GMy 0.256 0.267 ns
Sputum eosinophiliaz 1.3[0–43] 4.3[0–19] ns
Symptom score 0 0.471U0 ns
MA% mean 3.772.4 4.072.9 ns
With symptom recurrence n ¼ 34 FEV1% pred 97.7716.1 93.1712.7 0.01
PD20 methacholine, GMy 0.237 0.159 0.09
Sputum eosinophiliaz 1.8[0–56.5] 9.6[0–73.6] 0.0006
Symptom score 0 5.972U3 0.0001


























Figure 2 Sputum eosinophil percentage at T1 and at T2
in the two groups of patients with or without symptom
recurrence.
Predictors of asthma recurrence 627International Guidelines in long-term asymptomatic
stable asthmatics, leads to recurrence of asthma
symptoms in a high percentage of subjects in the
following three months. The recurrence of asthma
symptoms was predicted by the age of the patient
and duration of asthma, with age 440 yr and
asthma duration 45 yr showing a high positive
predictive value. Pulmonary function indices, in-
direct or direct methods of assessment of airway
inflammation or other clinical findings such as atopy
or rhinitis, could not predict the recurrence of
asthma.For long-term asthma treatment, international
guidelines recommend the use of the lowest
effective dose of ICS, which should be stopped
when patients have been asymptomatic and with
normal lung function for at least 3 months on low
dose ICS.1 This step-down strategy has been
suggested in order to limit the possible long-term
side effects of ICS, since the possibility to modify
the natural history of the disease with persistent
long-term treatment has not been clearly demon-
strated.3,14 However, the level of evidence for this
recommendation is poor, and indeed very few
studies have reported the rate of asthma recur-
rence after stepping down from level 2 to level 1
recommended treatment. Other studies have eval-
uated the possibility to predict asthma recurrence
when regular treatment was progressively reduced
or stopped using clinical, functional and biological
markers,5–9 but in these studies patients were not
on the minimum level of antiasthma treatment,
and were thus not suitable for treatment with-
drawal according to International Guidelines. In
these patients functional and biological findings
have been demonstrated to be poor predictors of
asthma recurrence.
Our subjects were in effect suitable for stopping
regular treatment, since they were on the lowest
level of antiasthma treatment and had been
asymptomatic during the last three months. The
stability of asthma was confirmed by the absence of
symptoms and of PEF variability, and by an FEV1
value in the normal range or at the best value
observed during the previous long-lasting observa-
tion period. According to international guidelines,
in such patients a further treatment step-down
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regular antinflammatory treatment. Thus, to the
best of our knowledge, our study is the first one
examining the rate of recurrence of asthma
symptoms after treatment cessation in mild persis-
tent patients. We confirmed that asthma symptoms
might recur in a 3-month interval in more than 50%
of patients. This fact suggests that asthma is a
persistent disease, and that regular treatment is
needed for most of a patient’s lifetime. Although a
recent paper suggests that as-needed treatment
can be as effective as regular treatment in mild
persistent asthmatic patients,15 the current guide-
lines for asthma continue to recommend regular
treatment when asthma symptoms are present at
least once a week.1
The main result of our study is that age 440 yr
and asthma duration 45 yr were the only indepen-
dent significant predictors of asthma recurrence; in
particular, combining age 440 yr and asthma
duration 45 yr obtained a 94% of predictive
positive value. This observation suggests that the
persistence of chronic airway inflammation induces
permanent changes in the airway wall (the so-
called ‘‘remodelling’’) that are responsible for the
persistence of functional abnormalities. Although
no clear relationship between duration of disease
and degree of remodelling has been demon-
strated, we might speculate that a longer persis-
tence of airway inflammation causes greater
structural changes leading to instability of disease
shortly after treatment cessation. Indeed, some
previous clinical and epidemiological studies
have correlated the persistence and/or the pro-
gression of chronic airway obstruction to the
duration of asthma,14,16,17 showing the relationship
between persistence of chronic inflammation and
‘‘irreversibility’’ of airway obstruction. Previous
studies on occupational asthma have already
demonstrated that the main determinants of the
persistence of asthma after cessation of occupa-
tional exposure to the specific sensitizer were
the duration of occupational exposure before
asthma onset and the duration of asthma before
diagnosis.18
The negative predictive effect of smoking habit
could be due to a misdiagnosis of asthma, as
subjects could be affected mainly by COPD, and in
this case exacerbation rate could be lower. How-
ever, the 19 current or ex-smokers had many
features of asthma (mean age 38.1+11.5 yr; dura-
tion of disease: 12.6+9.3 yr, mean FEV1:
99.0+15.5%, atopy in 15 out of 19); furthermore,
diagnosis of asthma has been performed according
to the usual recommended criteria1 at the time of
the first observation in our asthma clinic.In the present study we found no functional or
biological predictors of recurrence of asthma
symptoms. Previous studies reported no influence
of baseline bronchial responsiveness to methacho-
line on recurrence of asthma after cessation of
treatment.5 By contrast, sputum eosinophilia had
been reported as being associated to early recur-
rence of asthma after reduction or cessation of
corticosteroid treatment,6,8 but those studies were
conducted on a small number of subjects and the
predictive value of sputum eosinophilia was how-
ever low. In the present study, neither sputum
eosinophilia nor neutrophilia significantly predicted
the recurrence of asthma symptoms in the 3 months
following treatment cessation, suggesting that the
level of pre-existing airway inflammation, at least
as assessed by means of induced sputum, is not a
major determinant of the recurrence of asthma.
Smoking habit may affect the probability of
recurrence of asthma symptoms; in particular, ex-
smokers or current smokers at the time of enroll-
ment had a lower probability of asthma recurrence
after cessation of treatment with ICS. Although it
has been reported that current smoke is associated
with poorer control of asthma,19 some asthmatic
subjects may have never smoked because of a
greater severity of the disease which might there-
fore negatively affect the outcome of asthma
symptoms after cessation of treatment. Indeed,
true asthmatics are frequently non-smokers20 and
this fact may be due to a greater sensitivity of the
airways to the negative effect of cigarette smoke.
The study was unblinded, because it represented
the current recommended clinical practice. Thus,
subjects were aware of the cessation of the
treatment and this may have enhanced the
perception of asthma symptoms. However, the
recurrence of symptoms was confirmed by abnor-
mal PEF variability and by the increase in bronchial
hyperresponsiveness to methacholine and in spu-
tum eosinophil percentages at T2. In a previous
study, we demonstrated that the persistence of
low-dose inhaled corticosteroid treatment for 3
months in mild persistent well controlled asth-
matics was, associated with a very low rate of
recurrence of asthma symptoms or exacerbations,
in comparison with a high rate of recurrence of
asthma symptoms in subjects who discontinued
treatment.6 Another limit of our paper could be the
relatively low number of subjects examined.
Although the study sample is large as compared to
previous studies,5–9 a lack of power cannot be
excluded regarding some indicators with no statis-
tically significant difference, such as sex (61%
women with recurrence of asthma symptoms as
compared to 46% men).
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Predictors of asthma recurrence 629In conclusion, age and asthma duration were the
best predictors of asthma symptom recurrence in
mild persistent asthmatics who withdrew pharma-
cological therapy as recommended in the step-down
strategy by international guidelines. On the other
hand, bronchial hyperresponsiveness and sputum
cell counts were not useful in predicting the
recurrence of asthma symptoms after cessation of
regular treatment with ICS. This may be relevant
when the decision of ceasing treatment or not must
be taken in well-controlled mild asthmatic subjects.References
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